Introduction
============

Esophageal cancer is the eighth most common cancer and the sixth leading cause of cancer-related mortality worldwide. Globally, the number of new cases of esophageal cancer is about 480,000 and more than 400,000 deaths are attributable to this malignancy[@B1]. Esophageal squamous cell carcinoma (ESCC) is the dominant histological subtype in China[@B2]. Patients with esophageal cancer had a very poor prognosis because of the high rate of postoperative complications, recurrence and distant metastasis[@B3]. Although therapeutic approaches in targeted esophageal cancer have been improved in recent years, the 5-year survival rate is still about 40% by our previous studies [@B4], [@B5]. The process of esophageal carcinogenesis is a multi-step process. Both the disturbances of signal transduction pathways and the dysfunction of programmed cell death machinery have been demonstrated to be critical for cancer cells to survive and metastasis.

Programmed cell death (PCD) is a regulated cell death mediated by an intracellular program. Apoptosis, also called type I PCD, is characterized by nuclear fragmentation and chromosomal DNA fragmentation. Autophagy, type II PCD, is a vacuolar process of cytoplasmic degradation and characterized by autophagic vacuoles accumulating without apoptosis body forming and no chromosome condensing or caspase independence [@B6]. The molecular mechanism of autophagy involves several conserved Atg (autophagy-related) proteins. Beclin-1 (mammalian counterpart of the yeast Atg6) and LC3-II (mammalian homologues of yeast Atg8) are thought to be markers of autophagy. The decreased expression of Beclin-1 and LC3 had been found in gastric, lung and breast cancer and predicted the poor prognosis [@B7]-[@B9]. But there is still some controversy regarding the expression of Beclin-1 and LC3 proteins and their inhibitory effect on esophageal cancer. Some studies indicated that the decreased expression of Beclin-1 protein in ESCCs compared to normal esophageal epithelial cells and is correlated with a poor prognosis [@B10]. Conversely, a few studies had reached the opposite conclusions [@B11]. Therefore, the expression of Beclin-1 and LC3 in ESCCs has not been fully studied. The aim of our study is to investigate the expression of Beclin-1 and LC3 in human ESCC tissues, and their clinical pathological characteristics as well as prognosis.

Molecular profiling and genomics studies have revealed that the phosphoinositide 3-kinase/mammalian target of rapamycin (PI3K/mTOR) signaling pathway has been demonstrated to be activated in esophageal cancer [@B12], [@B13]. The PI3K/mTOR pathway is a critical regulator of autophagy induction[@B14], which activated mTOR suppresses autophagy and negative regulation of mTOR promotes it.

Histone deacetylases (HDACs) plays a critical role in the regulation of gene expression and has been shown to contribute to carcinogenesis by inducing the aberrant transcription of key genes regulating important cellular functions such as cell proliferation, cell-cycle regulation and PCD[@B15]. Inhibitors of HDACs exert anticancer activity by promoting acetylation of histones as well as by promoting acetylation of non-histone protein substrates, and represent promising potential targets for esophageal cancer treatment[@B16]. There are two main groups of mammalian HDACs, based on their homology with yeast counterparts. Class I, is homologous to Rpd3 in yeast, includes HDACs 1, 2, 3, and 8, has a nuclear localization, is ubiquitously expressed in human cell lines and tissues. Class II, contains HDAC 4, 5, 6, 7, 9, 10, is homologous to yeast Hda1, has the nucleus and cytoplasm expression. Both Class I and II HDACs are sensitive to the classical HDAC inhibitor trichostatin A (TSA).

Previous studies suggested that combined intervention of the PI3K/mTOR inhibitors and HDAC inhibitors could be more effective than single drugs in several human cancer cells, such as breast cancer, head and neck squamous cell carcinoma and NSCLC [@B17]-[@B19]. However, similar investigation of combining PI3K/mTOR inhibitor with HDAC inhibitor in esophageal cancer has not yet been reported. Thus, our study will investigate the anti-tumor effect of combination of PI3K/mTOR dual inhibitor BEZ235 and HDAC inhibitor TSA on the induction of apoptosis and autophagy in human ESCC cells.

Materials and methods
=====================

Patients and tissue samples
---------------------------

We selected an esophageal squamous cell carcinoma tissue and a paired non-tumor esophageal mucosa sample from 118 patients who had ESCC and underwent esophagectomy and lymph node dissections at the department of cardio-thoracic surgery of the Huashan Hospital during Jan 1, 2011 to Dec 31, 2013. Patients, who had palliative resections, underwent neoadjuvant or R1/R2 resections were excluded from the analysis. clinicopathologic characteristics as well as prognosis factors were collected. The institutional review board of Huashan hospital, Fudan University reviewed and approved the study.

Clinical data and follow up
---------------------------

Routine preoperative staging included fibro-gastroscopy, computed tomography of the chest and abdomen, ultrasound imaging of the abdomen and neck and PET-CT scanning. Preoperative nutritional risk assessment, cardiac function tests and pulmonary function test were also performed in all patients to make sure they had the physiological ability to undergo esophagectomy.

Esophageal cancer patients were staged according to the 8th edition AJCC staging system[@B20]. The standard follow up schedule contained: patients were followed every three months for 2 years, every six months for the next three years, and then annually. The outcome is all-cause mortality and defined as time from the data of surgery to the data of death. Routine postoperative tests contained fibro-gastroscopy, ultrasound, CT/PET-CT and radionuclide bone scan.

Cell culture and Reagents /antibodies
-------------------------------------

Human esophageal carcinoma cancer cell lines Eca-109 and TE-1 were obtained from the Cell Bank of Type Culture Collection of the Chinese Academy of Sciences, Shanghai Institute of Cell Biology (Shanghai, China). Eca-109 and TE-1 cells were cultured in PRMI 1640 medium (GIBCO BRL, Grand Island, NY, USA) and supplemented with 10% fetal bovine serum (FBS; GIBCO BRL), 100 U/mL penicillin and 100 U/mL streptomycin, and incubated at 37 °C in an atmosphere of 95 % air and 5 % CO2.

BEZ235 and TSA were purchased from Selleckchem (Houston, TX, USA). The antibodies against Beclin-1, LC3, p-Akt (Ser473), Akt, p-mTOR (Ser2448), mTOR, Bcl-2, p70S6K, p-p70S6K, Caspase-3, cleaved Caspase-3 and β-actin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).

Immunohistochemistry (IHC)
--------------------------

The sample-containing paraffin was sliced into serial sections with a width of 5.0 µm for immunohistochemical staining. Each section was deparaffinized for 1 hour at 60°C in xylene and rehydrated in serial graded ethanol before being stored overnight in citrate buffer (0.01 M, pH 6.0) at 75°C for antigen retrieval. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxide in methanol. The sections were incubated at 4°C overnight with a primary antibody (anti-LC3, mouse monoclonal antibody, 1:400 dilution and anti-Beclin-1, rabbit polyclonal antibody, 1:80 dilutions) and then recovered at 37°C for 20 minutes. The slides were incubated with the secondary antibody for 30 minutes at room temperature and then were developed by DAB. Nuclear staining was carried out with hematoxylin. Normal esophageal tissue was serving as the negative controls.

Evaluation of IHC staining
--------------------------

LC3 and Beclin-1 were considered positive by cytoplasmic and cytomembrane staining. The results were interpreted by two independent pathologists who were blinded to the specific diagnosis and prognosis for each case. For each sample, at least five fields were chosen randomly and at least 500 cells were required for scoring in each field. Staining extent of immunostaining was scored according to the percentage of positive stained cells as follows: 0, none; 1, up to 10% positive cells; 2, 10%-50% positive cells; 3, 51%-80% positive cells; 4, positive cells \> 80%. The intensity of staining was as follows: 0, none; 1, low-intensity (light yellow); 2, moderate-intensity (yellow); and 3, strong-intensity (reddish brown). The score was calculated as grade in stain intensity\*grade in coloration rate, which ranging from 0 to 12. The scores ≥4 were defined as positive over-expression. Low expression group included negative expression or low expression samples with overall score 0-3. Both the esophageal cancer tissue and the normal esophageal tissue use the same scoring criteria.

Cell viability assay
--------------------

Cell viability was measured using the MTT \[3-(4, 5-Dimethylthiazol-2-yl)-2, 5- diphenyl tetrazolium\] assay and colony formation test. Eca-109 cells were cultured in 96-well plates to adhere overnight, and were incubated 24 h prior to treatment. The cells were treated with BEZ235 (0, 50, 100, 200, 300, 500 and 800 nM), TSA (450 nM) or BEZ235 (150 nM) + TSA (450 nM) for 24-48 hours. Untreated cells were defined as controls. MTT (5 mg/mL) was added to each well followed by 4-hour incubation. 100 μL DMSO was added to dissolve the resulting formazan crystals. Absorbance values at 490 nm were determined. The experiments were repeated at least 3 times.

Western blot analysis
---------------------

Western blot analysis was carried out as we described previously, Target proteins were fractionated by SDS-PAGE and then electro-transferred into polyvinylidene difluoride membranes (Sigma, St. Louis, MO, USA). The membrane was blocked with 5% nonfat dry milk for 1 h at room temperature and subsequently incubated primary antibodies against p-Akt, Akt, p-mTOR, mTOR, Bcl-2, p70S6K, p-p70S6K, Caspase-3, cleaved Caspase-3, Beclin-1 and LC3 overnight at 4°C. After washing, the membranes were incubated with an anti-rabbit horseradish peroxidase antibody for 1 h at room temperature. The specific bands on the blots were visualized using a chemiluminescence detection kit (Thermo Fisher Scientific, Waltham, MA, USA). Protein expression levels were normalized to β-actin.

Statistical analysis
--------------------

The associations between IHC expression and clinicopathological variables were examined using χ2 test and Fisher\'s exact test for categorical variables and the Student\'s t test for continuous variables. The Kaplan-Meier survival curve and log-rank tests were performed to estimate the survival function across groups. Cox\'s proportional hazard regression model for multivariate analysis was performed to identify the independent prognostic factors. Vitro studies for comparison of multiple groups are presented as mean ± SD for at least three times. Unpaired t-tests were used for analyzing different variables (BEZ235 and TSA). Paired t-test analysis was used to compare different time points of the same variable (before and after treated with drug). Statistical analyses were performed using SPSS 16.0 software (SPSS, Inc., Chicago, USA). Significance was defined as *P* \< 0.05.

Results
=======

Patient Characteristics
-----------------------

The clinical characteristics and 5-years survival rate are summarized in **Table [1](#T1){ref-type="table"}**. There were 98 men and 20 women. The median age was 61 years (range, 38-82 years). The AJCC stage distribution was as follows: stage I, n=22 (18.6%); stage II, n = 48 (40.7%); stage III, n=37 (31.4%) and stage IV, n=11 (9.3%). The median follow-up time was 43 months.

Decreased expression of Beclin-1 and LC3 proteins in ESCCs
----------------------------------------------------------

The expression of Beclin-1 and LC3 were assessed in all 118 ESCC tissues and paired normal esophageal mucosa tissues by immunohistochemistry. Beclin-1 staining was observed mainly in the cytoplasm of the esophageal cancer cells while LC3 was observed in the cytoplasm and cytomembrane of cancer cells (**Figure [1](#F1){ref-type="fig"}**).

The immunohistochemistry results showed that 57.6 % (68/118) and 48.3 % (57/118) ESCC cells expressed Beclin-1 or LC3, respectively, 82.2 % (97/118) and 73.7 % (87/118) cells in paired normal tissues expressed Beclin-1 or LC3. The expression of both Beclin-1 and LC3 proteins were decreased significantly in ESCCs.

Relationship between Beclin-1, LC3 expression and clinicopathological features
------------------------------------------------------------------------------

We analyzed the correlations between Beclin-1, LC3 expression and clinical histopathologic parameters (**Table [2](#T2){ref-type="table"}**). Our study showed patients with positively expressed LC3 have a tender to have lower T-stages. Meanwhile, the negative expression of either Beclin-1 or LC3 was associated with advanced TNM stages (P = 0.006 and P\<0.001, respectively). Beclin-1 and LC3 protein expression did not show any association with age, gender, tumor location, surgical type and tumor differentiation (P \> 0.05).

For major preoperative comorbidities and postoperative complications, Highblood and fistula of esophageal anastomosis appeared to be more frequent in Beclin-1 negative patients.

We analyzed the association between LC3 and Beclin-1 protein expression. In the 68 Beclin-1 positive ESCC patients, 35 also had a positive expression of LC3. However, in the 50 Beclin-1 negative tumors, LC3 was not detected in 28 patients. We did not observe any significant association between LC3 and Beclin-1 expression (P = 0.427).

Our analysis results showed that Beclin-1 expression was negatively correlated with mTOR expression (P= 0.005). We could also found a tendency towards negative correlat767ion with LC3 and mTOR expression, but there was no significant difference (p=0.097).

Univariate and multivariate survival analysis
---------------------------------------------

The overall 1-, 3- and 5-year survival rate was 86.3%, 59.3% and 46.6%, respectively. The potential factors affecting overall survival by univariate analysis were tumor location (P = 0.034), T stage (P\<0.001), TNM stage (P\<0.001), Beclin-1 expression (P=0.007) and LC3 expression (P=0.021), as shown in **Table [1](#T1){ref-type="table"}**. High expression of Beclin-1 and LC3 predict better OS prognosis (**Figure [2](#F2){ref-type="fig"}**). Meanwhile, univariate survival analysis for disease-free survival (DFS) also showed similar results, patients with a high expression of Beclin-1 (54.3 % vs. 34.2%, p=0.023) or LC3 (58.6 % vs. 34.1%, p=0.014) had a better 5-year DFS rate.

The multivariate analysis indicated TNM stage and Beclin-1 expression (HR=0.511; 95% CI: 0.299-0.874, P=0.014) were significant risk factors (**Table [3](#T3){ref-type="table"}**). The expression of Beclin-1 was proved to be an independent prognostic factor for overall survival in ESCC patients.

Co-treatment with BEZ235 and TSA inhibits cell viability on Eca-109 and TE-1 cells
----------------------------------------------------------------------------------

To examine the inhibitory effect of BEZ235 and TSA on the proliferation of Eca-109 and TE-1 cells, we evaluated the cell viability before and after the increasing concentrations of BEZ235 or TSA ranging from 50 to 800 nM. As shown in **Figure [3](#F3){ref-type="fig"}**, the cell viability was significantly decreased after treatment with BEZ235 or TSA in both Eca-109 and TE-1 cells, indicating that both BEZ235 and TSA had dose dependent anti-tumor effects. The IC50 values for BEZ235 were 160.7 nM and 109.4 nM for Eca-109 and TE-1 cells, respectively. The IC50 values for TSA were 522.3 nM and 374.7 nM, respectively. And the two esophageal cancer cells were more sensitive to BEZ235. We set the indicated BEZ235 and TSA concentrations to 150 nM and 450nM respectively.

Effect of BEZ235 and TSA treatment on PI3K/mTOR pathway
-------------------------------------------------------

Firstly, we detected the expression of PI3K/mTOR pathway proteins in Eca-109 cells treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. The western blot results showed that BEZ235 inhibited the expression of p-mTOR, p-AKT and p-p70S6K in Eca-109 cells (*P*\<0.05). Moreover, the inhibition effect was dose dependent and significantly enhanced with the increasing dose of BEZ235 (**Figure [4](#F4){ref-type="fig"}A**).

Then, we detected the PI3K/mTOR pathway proteins after 48 hours of co-treatment of BEZ235 (150 nM) and TSA (450nM). As shown in **Figure [4](#F4){ref-type="fig"}B**, compare to BEZ235, TSA moderately affect the PI3K/mTOR pathway protein phosphorylation. After the combination with BEZ235 and TSA, it significantly inhibited the phosphorylation of mTOR, AKT and p70S6K in both Eca-109 and TE-1 cells relative to single drug.

Co-treatment with BEZ235 and TSA induces apoptosis and autophagy on Eca-109 and TE-1 cells
------------------------------------------------------------------------------------------

To explore whether co-treatment with BEZ235 (150 nM) and TSA (450nM) can induce apoptosis and autophagy, both apoptosis- and autophagy-related proteins were examined by western blot (**Figure [5](#F5){ref-type="fig"}**). Eca-109 and TE-1 cells were incubated with BEZ235 and TSA. We detected the apoptotic relative proteins caspase-3, cleaved caspase-3 and BCL-2. Compared to treatment with either drug alone, co-treatment with BEZ235 and TSA for 48 hours, the expression of cleaved caspase-3 was increased as well as the expression of caspase-3 and BCL-2 were decreased. These results suggested that co-treatment with BEZ235 and TSA synergistically induced apoptosis through both the mitochondrial pathway and the caspase-dependent pathway for cell death in ESCC cells.

Compared with treatment with either drug alone, the apoptotic relative proteins LC3-I, LC3-II and Beclin-1 were detected and immunoblotting analysis found co-treatment with BEZ235 and TSA significantly increased the expression of both LC3-II and Beclin-1 in ESCC cells, but the effect on the expression of LC3-I was no obvious (**Figure [6](#F6){ref-type="fig"}**). Therefore the co-treatment could also increase the ratio of LC3-II/LC3-I. Our finding indicated that co-treatment with BEZ235 and TSA exhibited anti-cancer effects through not only autophagy but also apoptosis pathways in ESCC cells.

Discussion
==========

Autophagy is regarded as a non-apoptotic form of PCD or called autophagic cell death and plays a fundamental role in the regulation of cell growth, proliferation, cell survival and cell death. Abnormal regulation of PCD is associated with a wide variety of human diseases, including cancer. And previous evidences showed autophagy is involved in the process of tumorigenesis in various solid tumors [@B21].

Beclin-1, the mammalian ortholog of yeast Atg6, is the first identified mammalian autophagy gene and created a core component of the PI3K-III complex. Beclin-1 plays an important role in recruiting proteins from the cytoplasm for autophagic degradation or in supplying the autophagic pathway with membrane components and involves in the initial step of autophagosome formation and is shown to be a positive regulator of autophagy and a tumor suppressor [@B22]. LC3 is an autophagosomal ortholog of yeast Atg8. During autophagy, the lipidated form of LC3 (LC3-II) is recruited to autophagosomal membranes. This conversion is considered to correlate with autophagic activity [@B23]. Thus, LC3-II has become a reliable marker for monitoring autophagy and autophagy-related processes [@B24].

There is a great deal of controversy about the role and effect of the autophagy-related proteins Beclin-1 and LC3 on solid tumor cell proliferation and prognosis. Several studies had found the down-regulated expression of Beclin-1 and LC3 proteins were correlated with poor survival in various tumors. Yu et al showed Beclin-1 and MAP1LC3B were lower in gastric cancer tissues than adjacent normal tissues and both the MAP1LC3B and Beclin-1 low expression patients had shorter OS time and RFS time [@B7]. Yang et al found the high expression of Beclin-1 in colorectal cancer and was correlated with histological grade and clinical stage and patients with a high Beclin-1 expression had a better OS and DFS [@B25]. On the contrary, Wu et al found the positive expression rates of Beclin-1 and LC3 in colorectal cancer tissues were higher than those in adjacent tissues [@B26].

Focusing on esophageal adenocarcinoma (EAC), previous studies almost got the same results that Beclin-1 expression was low in EAC tissues or cell lines [@B27], [@B28], and Weh et al found Beclin-1 expression loss occurred in 49.0% of EAC patients versus 4.8% of controls and there was a significant inverse correlation between loss of Beclin-1 with histologic grade and tumor stage.

So far the main controversy has focused on the expression and role of the two proteins on ESCCs. YS Chen et al found a loss of Beclin-1 protein expression in 33% of ESCCs, and the survival rate with Beclin-1 positive patients was significantly higher[@B10]. But Chen Y et al indicated the over-expression of Beclin1 and LC3 in esophageal cancer, and patients with Beclin1 and LC3 negative expression had a better OS [@B11]. In order to clarify the role and effect of autophagy-related proteins on ESCCs, we evaluated the two crucial autophagy-related proteins in 118 ESCC patients and found both Beclin-1 and LC3 expressions were significantly decreased in ESCC tissues compared with normal esophageal epithelial tissues. Meanwhile, our study found both Beclin-1 and LC3 expressions were significantly correlated with the T-stage and the AJCC TNM stage. Patients with a high expression of Beclin-1 or LC3 had a better OS or DFS. These finding indicated that autophagy plays an important role in the development and prognosis of ESCCs. In order to explore the molecular mechanism of autophagy and verify whether the inhibition of autophagy had potential value in anti-cancer therapy in ESCCs.

The PI3K/mTOR pathway dysregulation has been found in various tumors and plays a crucial role in regulation of cell proliferation, apoptosis and autophagy. Our previous studies had found PI3K/mTOR pathway was aberrantly activated in ESCCs, and the present study found both Beclin-1 and LC3 expression had a tendency towards negative correlation with mTOR expression. Thus, the PI3K/mTOR inhibitors are appealing pharmacologic target in esophageal cancer treatment.

Our study found BEZ235, the dual inhibitor of mTOR and PI3K can reduce viability of ESCC cells in a dose-dependent manner caused by the significant reduction in p-Akt, p-mTOR and p-p70S6K activity on Eca-109 and TE-1 cells. After BEZ235 intervention, the autophagy or apoptosis-related proteins beclin-1, LC3-II, ratio of LC3-II/LC3-I and cleaved caspase-3 were increased as well as caspase-3 and BCL-2 decreased. The study reveals that BEZ235 inhibits the PI3K/mTOR pathway and induces the autophagy and apoptosis in human esophageal cancer cells.

Epigenetic mechanisms, such as modifications of DNA-structure or histone modification play particularly important roles in controlling PCD, such as autophagy, apoptosis and necroptosis in tumor cells. The up-regulated of HDAC has been observed in several types of solid tumors, including non-small cell lung cancer, breast cancer and so on[@B17], [@B19]. HDAC inhibitors cause changes in the acetylation status of chromatin and other non-histone proteins, resulting in changes in gene expression, induction of apoptosis and inhibition of angiogenesis and metastasis. In recent years, more studies focused on the development of small molecule enzyme inhibitors of histone-modifying enzymes and HDAC inhibitor may reverse misregulated epigenetic states and has been seen as a promising therapy of cancer[@B15].

Recently studies indicated that combined PI3K/mTOR inhibitor with HDAC inhibitor may be more effective than a single drug intervention in various human tumor cells. Chen et al found co-treatment with BEZ235 and TSA enhanced autophagic cell death and blocked tumor growth without noticeable side effects in breast cancer [@B17]. Erlich et al. reported that the combination with the HDAC inhibitor Panobinostat and the PI3K/mTOR inhibitor BGT226 and BEZ235 could inhibit the viability of head and neck squamous carcinoma cells better than single drug [@B18]. Some previous studies had reported that HDAC inhibitor TSA could suppresses proliferation and promotes apoptosis of esophageal squamous cell lines [@B29]-[@B31]. But the effect of combination of HDAC inhibitors and PI3K/mTOR inhibitor on ESCCs is still unknown. Our recently study found co-treatment with BEZ235 and TSA could inhibit the growth and visibility in human esophageal cancer Eca-109 and TE-1 cells and enhanced autophagic cell death by up-regulating the expression of LC3-II and Beclin-1. Meanwhile, co-treatment with BEZ235 and TSA can increase the expression of cleaved caspase-3 and decrease the expression of caspase-3 and BCL-2. These results suggested that co-treatment with BEZ235 and TSA synergistically induced apoptosis and autophagy.

To our knowledge, this is the first study investigating the combination of mTOR and HDAC inhibitors in human esophageal squamous cell carcinoma cells. The previous studies revealed that HDAC inhibitors can potentially augment the anticancer activity of PI3K/mTOR pathway inhibition by further reducing AKT activation. Thus our finding suggested that compared with either drug alone, combining PI3K/mTOR and HDAC-inhibitors can significantly inhibit the viability and induce the programmed cell death, such as autophagy and apoptosis in ESCC cells through the mechanistic convergence onto the PI3K/mTOR pathway.

In summary, our study showed the Beclin-1 and LC3 were lower in ESCC tissues than adjacent normal tissues, and the high expression of Beclin-1 and LC3 were favorable prognostic indicators of overall survival. The activation of the PI3K/mTOR pathway is observed in ESCCs compared with normal esophageal mucosa, which can block autophagy and induce the decreasing expressions of autophagy-related proteins such as Beclin-1, LC3-II and the ratio of LC3-II/LC3-I. Co-treatment with BEZ235 and TSA is more effective than single drug in inhibiting the viability of ESCC cells in Vitro through inducing apoptosis and autophagy, which can be a new effective therapeutic target in ESCCs.
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AJCC

:   American Joint Committee on Cancer

CI

:   confidence interval

HR

:   hazard ratio

OS

:   overall survival

DFS

:   disease-free survival

ESCC

:   esophageal squamous cell carcinoma

EAC

:   esophageal adenocarcinoma

HDAC

:   histone deacetylase

TSA

:   Trichostatin A

PCD

:   Programmed cell death

PI3K/mTOR

:   phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin.

![Immunohistochemical analysis of Beclin-1 and LC3 in ESCCs. High expression (A) and low expression (B) of Beclin-1 in cytoplasm of tumor cells. High expression (C) and low expression (D) of LC3 in cytoplasm and cytomembrane of tumor cells. A-D: 20x magnification.](jcav09p0987g001){#F1}

![Cumulative Kaplan-Meier survival curves. A. Curves of OS for patients with Beclin-1 positive and Beclin-1 negative tumors. B. Curves of OS for patients with LC3 positive and LC3 negative tumors. C. Curves of OS for all patients.](jcav09p0987g002){#F2}

![Cell viability of Eca-109 and TE-1 cells, treated by either BEZ235 (A) or TSA (B) for 48h, was measured by MTT assay. C. Co-treatment of BEZ235 and TSA showed synergistically cytotoxic effect on ESCC cells. Each cell was analyzed in three times. \*p\<0.05 compared with control by t-test.](jcav09p0987g003){#F3}

![Effect of treatment with BEZ235 or TSA on PI3K/mTOR pathway in ESCC cells. A. Eca-109 cells was treated with increasing concentration of BEZ235 (0, 100, 200 and 500 nM) for 48 hours. Western blot showed the inhibition effect of PI3K/mTOR pathway was dose dependent. B. Co-treatment of BEZ235 (150 nM) and TSA (450 nM) for 48 hours increased inhibition of the PI3K/mTOR pathway in Eca-109 and TE-1 cells. Each protein was analyzed in three times, and one representative experiment is shown.](jcav09p0987g004){#F4}

![Apoptosis induced by co-treatment with BEZ235 and TSA in ESCC cells. A. Co-treatment of BEZ235 (150 nM) and TSA (450 nM) for 48 hours, western blot showed the expression of cleaved caspase-3 was increased as well as the expression of caspase-3 and BCL-2 were decreased. Percentage of apoptotic proteins expression of Eca-109 (B) and TE-1 (C) cell, compared to control. \*p\<0.05 compared with control and single reagent.](jcav09p0987g005){#F5}

![Autophagy induced by co-treatment with BEZ235 and TSA in ESCC cells. A Co-treatment of BEZ235 (150 nM) and TSA (450 nM) for 48 hours, significantly increased the expression of both LC3-II and Beclin-1. Percentage of autophagic proteins expression of Eca-109 (B) and TE-1 (C) cell, compared to control. \*p\<0.05 compared with control and single reagent.](jcav09p0987g006){#F6}

###### 

Patient characteristics and univariate analysis

  Factors               No.   5-year survival (%)   *p*
  --------------------- ----- --------------------- -----------
  **Age, year**                                     
  ≤65                   83    45.3%                 0.662
  \>65                  35    48.8%                 
  **Sex**                                           
  Male                  98    49.2%                 0.295
  Female                20    35%                   
  **Tumor location**                                
  Upper                 17    29.4%                 **0.034**
  Middle                68    52.3%                 
  Lower                 33    43.7%                 
  **Surgical type**                                 0.107
  2-FL                  60    52.3%                 
  3-FL                  58    41.1%                 
  **Differentiation**                               
  Well                  8     87.5                  0.117
  Moderately            73    40.7                  
  Poorly                37    50.3                  
  **T stage**                                       
  T1+ T2                60    66.1                  **0.000**
  T3+T4                 58    26.3                  
  **TNM stage**                                     
  I                     22    85.2                  **0.000**
  II                    48    59.7                  
  III                   37    18.1                  
  IV                    11    13.6                  
  **Beclin-1**                                      
  Positive              68    54.5                  **0.007**
  Negative              50    35.1                  
  **LC3**                                           
  Positive              57    61.3                  **0.021**
  Negative              61    33.0                  

###### 

Associations of beclin-1 and LC3 expressions with chinicopathologic characteristics in ESCCs.

  -----------------------------------------------------------------------------------
  Factors                  No   Beclin-1   *p*\   LC3         *p*\        
  ------------------------ ---- ---------- ------ ----------- ------ ---- -----------
  **Age**                                                                 

  ≤65                      83   50         33     0.381       37     46   0.216

  \>65                     35   18         17                 20     15   

  **Sex**                                                                 

  Male                     98   54         44     0.223       49     49   0.419

  Female                   20   14         6                  8      12   

  **Tumor location**                                                      

  Upper                    17   11         6      0.520       8      9    0.434

  Middle                   68   39         29                 36     32   

  Lower                    33   18         15                 13     20   

  **Surgical type**                                                       

  2-FL                     60   37         23     0.371       31     29   0.462

  3-FL                     58   31         27                 16     32   

  **Differentiation**                                                     

  Well                     8    4          4      0.226       7      1    0.750

  Moderately               73   47         26                 28     45   

  Poorly                   37   17         20                 22     15   

  **T stage**                                                             

  T1+ T2                   60   39         21     0.101       37     23   **0.003**

  T3+T4                    58   29         29                 20     38   

  **TNM stage**                                                           

  I                        22   17         5      **0.006**   17     5    **0.000**

  II                       48   30         18                 28     20   

  III                      37   15         22                 8      29   

  IV                       11   6          5                  4      7    

  **Comorbidities**                                                       

  Highblood                60   27         33     **0.004**   28     32   0.720

  Copd                     13   9          4      0.374       8      5    0.316

  Cardiovascular disease   19   11         8      0.980       12     7    0.160

  Arrhythmia               11   6          5      0.830       4      7    0.410

  Diabetes                 40   23         17     0.984       17     23   0.370

  **Complications**                                                       

  90-day mortality         4    1          3      0.017       2      2    0.946

  Fistula                  13   4          9      **0.038**   5      8    0.456

  Sepsis                   11   4          7      0.136       6      5    0.667

  Pneumonia                56   32         24     0.920       30     26   0.281

  cardiac insufficiency    21   12         9      0.961       9      12   0.585

  **mTOR**                                                                

  Positive                 62   28         34     **0.005**   25     37   0.097

  Negative                 56   40         16                 32     24   

  **LC3**                                                                 

  Positive                 57   35         22     0.427                   

  Negative                 61   33         28                             
  -----------------------------------------------------------------------------------

###### 

Multivariate prognostic analyses of overall survival

  Prognostic factors       *P* values   HR      95% *CI*
  ------------------------ ------------ ------- -------------
  Tumor location           0.291        0.781   0.494-1.236
  T-stage (T1+2 vs T3+4)   0.449        1.297   0.662-2.542
  TNM-stage                0.001        1.893   1.293-2.773
  Beclin-1                 0.014        0.511   0.299-0.874
  LC3                      0.526        1.201   0.681-2.118
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